What’s Changing in 2019: Market Access Challenges with Anti-VEGF Therapies
3/30/2019 6:30 pm – 8:30 pm
Four Seasons Dallas at Las Colinas
Irving, Texas
Save to your calendar
Description
The introduction of anti-VEGF agents for the treatment of age-related macular degeneration (AMD), diabetic retinopathy (DR), and retinal vein occlusion (RVO), transformed the management of these conditions. While the clinical benefits of these compounds are well documented their use brings up other issues for ophthalmologists, namely, cost. Thus, payers have become more involved in managing the use of these agents, potentially interfering with clinical decision making. This live event brings together thought leaders in the retina field to discuss the challenges they face in obtaining access to anti-VEGF medications for their patients, and how they overcome those challenges.
Contact: Alan Guralnick; alan@evolvemeded.com
Web URL: https://bmcg.regfox.com/2019-evolve-market-access